No one seems to get that this patent approval is not the one or scope the docs were expecting. This approval is for the ENTIRE platform. This approval, if I read the PR correctly, means Allexcel, and therefore NNVC, owns the exclusive rights for the entire base and that no one can legally reverse engineer the platform and simply slap a new set of ligands to the structure and call it an improvement. This protection extends to all countries in the WPO. This news is huge, and it makes the follow-on patent applications for antiviral use a slam dunk and nothing more than a possible strategy for extending patent protection a few more years. <br /> <br /> The company owns the entire approach! This ownership will include the original intent for the technology, a therapeutic courier for targeted drug delivery such as RNA therapies. <br /> <br /> <br /> This is huge!